Is it possible to diagnose acute hepatitis C virus (HCV) infection by a rising anti-HCV titre rather than by seroconversion?

Journal of Viral Hepatitis

Volumn 11, Issue 6, 2004, Pages 563-570

  Lu, Sheng Nan ^a   Tung, H D ^a   Chen, T M ^a,b   Lee, C M ^a   Wang, J H ^a   Hung, C H ^a   Chen, C H ^a   Changchien, C S ^a  

^a CHANG GUNG MEMORIAL HOSPITAL   (Taiwan)

^b TUNGS' TAICHUNG METROHARBOR HOSPITAL   (Taiwan)

Author keywords

Acute hepatitis C; Anti HCV; Recombinant immunoblot assay; Seroconversion

Indexed keywords

ACUTE HEPATITIS; ADULT; AGED; ANTIBODY TITER; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; ENZYME IMMUNOASSAY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOBLOTTING; INTERMETHOD COMPARISON; MALE; PRIORITY JOURNAL; SEROCONVERSION;

ACUTE DISEASE; ADULT; AGED; FEMALE; HEPACIVIRUS; HEPATITIS C; HEPATITIS C ANTIBODIES; HUMANS; IMMUNOBLOTTING; MALE; MIDDLE AGED; RECOMBINANT PROTEINS; RNA, VIRAL; VIRAL NONSTRUCTURAL PROTEINS;

EID: 8444244520     PISSN: 13520504     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2893.2004.00533.x     Document Type: Article

References (29)

1. Alter HJ. New kit on the block: evaluation of second-generation assays for detection of antibody to the hepatitis C virus. Hepatology 1992; 2: 350-353.
2. Vrielink H, Reesink HW, van den Burg PJM et al. Performance of three generations of anti-hepatitis C virus enzyme linked immunosorbent assays in donors and patients. Transfusion 1997; 37: 845-849.
3. Hennig H, Schlenke P, Kirchner H, Bauer I, Schulte-Kellinghaus B, Bludau H. Evaluation of newly developed microparticle enzyme immunoassays for the detection of HCV antibodies. J Virol Methods 2000; 84: 181-190.
4. Lu SN, Chue PY, Chen IL et al. Incidence of hepatitis C infection in a hepatitis C endemic township in southern Taiwan. Kaohsiung J Med 1997; 13: 605-608.
5. Sun CA, Chen HC, Lu CF et al. Transmission of hepatitis C virus in Taiwan: prevalence and risk factors based on a nationwide survey. J Med Virol 1999; 59(3): 290-296.
6. Alter MJ, Mast EE. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 1994; 23(3): 437-455.
7. Tung HD, Lu SN, Lee CM et al. Antiviral treatment responses in patients with chronic hepatitis C virus infection evaluated by a third generation anti-hepatitis C virus assay. J Viral Hepat 2002; 9: 304-308.
8. Huang WS, Lu SN, Wang JH et al. Prediction of viremia for case of hepatitis C virus (HCV) infection using a third-generation anti-HCV enzyme immunoassay test. Hepatogastroenterology 2004 (in press).
9. Courouce AM, Le Marrec N, Girault A, Ducamp S, Simon N. Anti-hepatitis C virus (anti-HCV) seroconversion in patients undergoing hemodialysis: comparison of second- and third-generation anti-HCV assays. Transfusion 1994; 34(9): 790-795.
10. Barrera JM, Bruguera M, Ercilla MG et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C. Hepatology 1995; 21(3): 639-644.
11. Jaeckel E, Cornberg M, Wedemeyer H et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med 2001; 345: 1452-1457.
12. Kondili LA, Chionne P, Costantino A et al. Infection rate and spontaneous seroreversion of anti-hepatitis C virus during the natural course of hepatitis C virus infection in the general population. Gut 2002; 50(5): 693-696.
13. Lefrere JJ, Guiramand S, Lefrere F et al. Full or partial seroreversion in patients infected by hepatitis C virus. J Infect Dis 1997; 175(2): 316-322.
14. Giuberti T, Ferrari C, Marchelli S et al. Long-term follow-up of anti-hepatitis C virus antibodies in patients with acute non-A non-B hepatitis and different outcome of liver disease. Liver 1992; 12(2): 94-99.
15. Yuki N, Hayashi N, Hagiwara H et al. Changes in antibodies to specific hepatitis C virus antigens with interferon-alpha therapy: analysis by recombinant immunoblot assay. Am J Gastroenterol 1993; 88(6): 914-918.
16. Hofer H, Watkins-Riedel T, Janata O et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicated by repeated measurements of serum viral load. Hepatology 2003; 37: 60-64.
17. Giuberti T, Marin MG, Ferrari C et al. Hepatitis C virus viremia following clinical resolution of acute hepatitis C. J Hepatol 1994; 20(5): 666-671.
18. Berg T, Pascu M, Moller B. Prediction of spontaneous viral clearance in acute hepatitis C by viral load measurements. Hepatology 2003; 37(6): 1495-1496.
19. Gerlach JT, Diepolder HM, Jung M-C et al. Recurrence of hepatitis C virus after loss of virus specific CD4+ T-cell response in acute hepatitis C. Gastroenterology 1999; 117: 933-941.
20. Villano SA, Vlahov D, Nelson KE, Conn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection. Hepatology 1999; 29(3): 908-914.
21. Huang JF, Lu SN, Chue PY et al. Hepatitis C virus infection among teenagers in an endemic township in Taiwan: epidemiological and clinical follow-up studies. Epidemiol Infect 2001; 127(3): 485-492.
22. Payan C, Raimbert A, Fouchard-Hubert I, Kouyoumdjian S, Lunel-Fabiani F. Quantitative antibody analysis: use for the diagnosis of hepatitis C virus chronic infection. Ann Biol Clin (Paris) 2003; 61(3): 311-317.
23. Kuwana K, Ichida T, Kamimura T et al. Risk factors and the effect of interferon therapy in the development of hepatocellular carcinoma: a multivariate analysis in 343 patients. J Gastroenterol Hepatol 1997; 12(2): 149-155.
24. Yoshida H, Shiratori Y, Moriyama M et al. Interferon therapy reduces the risk for hepatocellular carcinoma: national surveillance program of cirrhotic and noncirrhotic patients with chronic hepatitis C in Japan. Ann Intern Med 1999; 131: 174-181.
25. Papatheodoridis GV, Papadimitropoulos VC, Hadziyannis SJ. Effect of interferon therapy on the development of hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis: a meta-analysis. Aliment Pharmacol Ther 2001; 15(5): 689-698.
26. International Interferon-alpha Hepatocellular Carcinoma Study Group. Effect of interferon-alpha on progression of cirrhosis to hepatocellular carcinoma: a retrospective cohort study. Lancet 1998; 23: 1535-1539.
27. Omata M, Yoshida H. Resolution of liver cirrhosis and prevention of hepatocellular carcinoma by interferon therapy against chronic hepatitis C. Scand J Gastroenterol Suppl 2003; 38(237): 47-51.
28. Tanaka K, Sata M, Uchimura Y, Suzuki H, Tanikawa K. Long-term evaluation of interferon therapy in hepatitis C virus-associated cirrhosis: does IFN prevent development of hepatocellular carcinoma? Oncol Rep 1998; 5(1): 205-208.
29. Vogel W. Treatment of acute hepatitis C virus infection. J Hepatol 1999; 31(Suppl. 1): 189-192.